Sponsors

Founded in 2015 and based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Kezar believes that the immunoproteasome is a validated target for the treatment of a wide variety of autoimmune diseases given the compelling published activity seen with non-selective proteasome inhibitors administered to patients with severe autoimmune diseases. Kezar is currently recruiting patients to participate in Phase 2 clinical trials. The diseases being studied in these trials are: lupus nephritis, dermatomyositis, polymyositis, autoimmune hemolytic anemia, and immune thrombocytopenia.

Steve Powell, founder of IndeeLift sought out the help of several inclusion body myositis patients, IBMer’s, to adapt the residential lift to meet the needs of Myositis patients, now lifting to a standing position.

Steve says, “IndeeLift is becoming larger and more successful by living with the philosophy people count! All of our efforts are being aimed at achieving the greatest good for the greatest number in all that we do! Consequently, IndeeLift is partnering with Myositis Support and Understanding and the Myositis Community and as such, Myositis will be the primary recipient of IndeeLift corporate giving efforts for the foreseeable future! Together we can really make a difference in the day-to-day lives in this community, while also enabling the research that may one day lead to the real goal of slowing or curing IBM and ultimately Myositis.”

To learn more about the new HLF, how it can help you regain and maintain your independence, and IndeeLift’s plans to help the Myositis Community, visit the MSU Indeelift Program page.

CSI Pharmacy is a nationwide specialty pharmacy, founded by pharmacists, dedicated to servicing patients with chronic and rare illnesses requiring complex care. We are invested in improving the health—and the lives—of the people we serve by offering expert clinicians, passionate advocates, committed healthcare partners and strategic reimbursement experts. Our goal is to optimize patient outcomes, while treating patients as if they were members of our family. Twenty percent of the patients we treat have a form of myositis. We are proud to be a sponsor of MSU!

Orphazyme is a late-stage biopharmaceutical company focused on developing novel treatment options for patients with rare, orphan diseases. Our work is focused on the cell-protective properties of the heat-shock response, a natural defense mechanism in all our cells. Orphazyme’s lead compound, arimoclomol, is being developed as a potential treatment for several protein-misfolding diseases, including sporadic inclusion body myositis (sIBM). A phase 2/3 clinical trial investigating the use of arimoclomol for sIBM is ongoing with results expected in the first half of 2021.